Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Subscribe To Our Newsletter & Stay Updated